Brown University, 122 Shaw Ave, Cranston, RI 02905-3833, USA.

This email address is being protected from spam bots, you need Javascript enabled to view it

To review the efficacy and safety of fesoterodine, a new antimuscarinic for treating overactive bladder (OAB) symptoms.

Review of efficacy and safety data from the pivotal phase 3 trials of fesoterodine for the treatment of OAB. Although there were a number of additional end points, they were not included in the US prescribing information for fesoterodine and thus are not included in this article.

OAB is a chronic condition affecting both men and women. The principal symptom is urgency, with or without urgency incontinence, with some patients experiencing increased daytime frequency and nocturia. In two 12-week, randomized, double-blind, phase 3 trials, fesoterodine 4 and 8 mg administered once daily were significantly better than placebo in alleviating OAB symptoms, as determined by changes in bladder diary variables. Both doses of fesoterodine were well tolerated.

Fesoterodine is an efficacious, well-tolerated treatment for OAB.

Written by:
Ellsworth P, Berriman SJ, Brodsky M. Are you the author?

Reference:
Am J Manag Care. 2009 Mar;15(4 Suppl):S115-7.

PubMed Abstract
PMID:19355800

UroToday.com Overactive Bladder (OAB) Section

Please log-in or register in order to submit comments.

Powered by AkoComment!